Bosutinib Isomer 1, Free Base (CAS 1391063-17-4)
QUICK LINKS
Bosutinib Isomer 1, Free Base, represents a variant of the bosutinib molecule with an altered structural arrangement, diverging from the parent compound in its specific interaction with cellular targets. Despite its deviation from the canonical bosutinib structure, leading to a diminished capacity to inhibit a broad spectrum of kinases, this isomer retains a potent activity against Bcr-Abl kinase, a pivotal enzyme in certain cellular signaling pathways. Its ability to selectively engage and inhibit Bcr-Abl kinase positions Bosutinib Isomer 1, Free Base as useful in the exploration of the complex signaling mechanisms mediated by this kinase. In research applications, it facilitates the dissection of Bcr-Abl′s role within various cellular processes, offering insights into the enzyme′s contribution to the regulation of cell growth and proliferation pathways.
Bosutinib Isomer 1, Free Base (CAS 1391063-17-4) References
- In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. | Filppula, AM., et al. 2014. Drug Metab Dispos. 42: 1202-9. PMID: 24713129
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bosutinib Isomer 1, Free Base, 25 mg | sc-396752 | 25 mg | $77.00 |